Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.45) by 8.89 percent. This is a 18.33 percent increase over losses of $(0.60) per share from the same period last year.